Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "March"

912 News Found

Orchid Pharma launches Rs. 500 Cr QIP programme
News | December 02, 2022

Orchid Pharma launches Rs. 500 Cr QIP programme

With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023


Gland Pharma to buy French pharma company Cenexi
News | November 30, 2022

Gland Pharma to buy French pharma company Cenexi

Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group


Japan approves ENHERTU for treatment of adult patients with HER2 positive unresectable breast cancer
Drug Approval | November 27, 2022

Japan approves ENHERTU for treatment of adult patients with HER2 positive unresectable breast cancer

Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial


Orchid Pharma reports positive EBIDTA in Q2
News | November 15, 2022

Orchid Pharma reports positive EBIDTA in Q2

The company is focussed on increasing the capacity utilizations while controlling costs


Dr. Lucica Ditiu appreciates India's TB elimination response
Policy | November 11, 2022

Dr. Lucica Ditiu appreciates India's TB elimination response

Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company


Advent International launches Cohance Lifesciences
News | November 02, 2022

Advent International launches Cohance Lifesciences

API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories


Quizartinib granted priority review in the U.S.
Drug Approval | October 26, 2022

Quizartinib granted priority review in the U.S.

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone


Matt Sause elevated as new CEO of Roche Diagnostics
People | October 04, 2022

Matt Sause elevated as new CEO of Roche Diagnostics

Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.


Lupin receives warning letter from US FDA
Drug Approval | September 30, 2022

Lupin receives warning letter from US FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility